Morphine Side Effects in β-Arrestin 2 Knockout Mice

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2005-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1124/JPET.105.087254
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• G protein-coupled receptor kinase/β-arrestin systems and drugs of abuse

  2007influential reference
• Transduction of Receptor Signals by ß-Arrestins

  2005cited by this paper
• G protein-coupled receptor kinase/beta-arrestin systems and drugs of abuse: psychostimulant and opiate studies in knockout mice.

  2004cited by this paper
• G protein-coupled receptor kinase 5 regulates airway responses induced by muscarinic receptor activation.

  2004cited by this paper
• Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery.

  2004cited by this paper
• Spinophilin Blocks Arrestin Actions in Vitro and in Vivo at G Protein-Coupled Receptors

  2004cited by this paper
• Desensitization of G protein-coupled receptors and neuronal functions.

  2004cited by this paper
• Dopaminergic Supersensitivity in G Protein-Coupled Receptor Kinase 6-Deficient Mice

  2003cited by this paper
• Comparison of morphine-6-glucuronide and morphine on respiratory depressant and antinociceptive responses in wild type and mu-opioid receptor deficient mice.

  2003cited by this paper
• Enhanced Rewarding Properties of Morphine, but not Cocaine, in βarrestin-2 Knock-Out Mice

  2003cited by this paper
• 5-HT4(a) Receptors Avert Opioid-Induced Breathing Depression Without Loss of Analgesia

  2003cited by this paper
• Differential Mechanisms of Morphine Antinociceptive Tolerance Revealed in βArrestin-2 Knock-Out Mice

  2002cited by this paper
• The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals.

  2002cited by this paper
• Anesthetic Potency and Influence of Morphine and Sevoflurane on Respiration in &mgr;-Opioid Receptor Knockout Mice

  2001cited by this paper
• Activation and targeting of extracellular signal-regulated kinases by β-arrestin scaffolds

  2001cited by this paper
• Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence.

  2000influential reference
• μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence

  2000influential reference
• Clinical pharmacology and adverse effects

  1999cited by this paper
• Muscarinic Supersensitivity and Impaired Receptor Desensitization in G Protein – Coupled Receptor Kinase 5 – Deficient Mice

  1999cited by this paper
• Enhanced morphine analgesia in mice lacking beta-arrestin 2.

  1999influential reference
• Opioids in Pain Control: Frontmatter

  1998cited by this paper
• Respiratory effects of pressor and depressor agents in conscious rats.

  1998cited by this paper
• Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor.

  1998cited by this paper
• mu-Opioid receptor-knockout mice: the role of mu-opioid receptor in gastrointestinal transit.

  1998influential reference
• Activity of the δ-Opioid Receptor Is Partially Reduced, Whereas Activity of the κ-Receptor Is Maintained in Mice Lacking the μ-Receptor

  1998cited by this paper
• μ-Opioid receptor-knockout mice: the role of μ-opioid receptor in gastrointestinal transit

  1998cited by this paper
• Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness.

  1998cited by this paper
• Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography.

  1997cited by this paper
• Opioid analgesics and antagonists

  1996cited by this paper
• Antidiarrheal and colonic antipropulsive effects of spinal and supraspinal administration of the natural delta opioid receptor agonist, [D-Ala2]deltorphin II, in the rat.

  1992cited by this paper
• Comparison of naloxonazine and beta-funaltrexamine antagonism of mu 1 and mu 2 opioid actions.

  1991cited by this paper
• Relationship between analgesia and respiratory depression for mu opioid receptor agonists in mice.

  1991cited by this paper
• Comparison of naloxonazine and β-funaltrexamine antagonism of μ1 and μ2 opioid actions

  1991cited by this paper
• Antidiarrheal properties of supraspinal mu and delta and peripheral mu, delta and kappa opioid receptors: inhibition of diarrhea without constipation.

  1989cited by this paper
• Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model.

  1989cited by this paper
• Colonic bead expulsion time in normal and μ-opioid receptor deficient (CXBK) mice following central (ICV) administration of μ- and δ-opioid agonists

  1987cited by this paper
• Colonic bead expulsion time in normal and mu-opioid receptor deficient (CXBK) mice following central (ICV) administration of mu- and delta-opioid agonists.

  1987cited by this paper
• Goodman and Gilman's the Pharmacological Basis of Therapeutics

  1986cited by this paper
• Evidence for a role of conditioning in the development of tolerance to morphine-induced inhibition of gastrointestinal transit in rats.

  1986cited by this paper
• Opioids and breathing.

  1985cited by this paper
• Separation of opioid analgesia from respiratory depression: evidence for different receptor mechanisms.

  1985cited by this paper
• Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse.

  1984cited by this paper
• Relative involvement of receptor subtypes in opioid-induced inhibition of intestinal motility in mice.

  1982cited by this paper
• Centrally and peripherally mediated inhibition of intestinal motility by opioids

  1979cited by this paper
• Receptor affinity and pharmacological potency of a series of narcotic analgesic, anti-diarrheal and neuroleptic drugs.

  1977cited by this paper
• Central nervous respiratory depressants--narcotic analgesics.

  1977cited by this paper
• Loperamide binding to opiate receptor sites of brain and myenteric plexus.

  1976cited by this paper
• A barometric method for measuring ventilation in newborn infants.

  1955cited by this paper

• Opioid Receptors in Psychedelia: Indirect Serotonergic Modulation of Direct KOR Activation by Salvinorin A.

  2026cites this paper
• Divergence in μ and δ opioid receptor pharmacology in neurons and antinociceptive efficacy in neuropathic pain: Insights from MP135 and CYM51010.

  2026cites this paper
• The Role of Danavorexton for Perioperative Opioid-Induced Respiratory Depression and Sedation: A Narrative Review

  2026cites this paper
• Development and validation of an LC-MS/MS method for quantifying a new G protein selective μ-opioid receptor agonist YZJ-4729 and its major metabolite M10 in human plasma to support a phase I study in healthy subjects.

  2025cites this paper
• Discovery, SAR, and molecular basis of (R)-1-((3R,4S)-3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)piperidin-1-yl)-3-(3-fluorophenyl)-2-methylpropan-1-one as a novel potent analgesic.

  2025cites this paper
• Rational Design Biased Compounds against μ‑Opioid Receptor.

  2025cites this paper
• Comparison of Oliceridine and Morphine in Postoperative Analgesia in Laparoscopic Total Hysterectomy, a Randomized Double-Blind Controlled Trial

  2025cites this paper
• Biased agonism in peptide-GPCRs: A structural perspective.

  2025cites this paper
• Therapeutic exploration of biased ligands at class A G protein-coupled receptors over the past 20 years.

  2025cites this paper
• Impact of G protein-coupled receptor conformation on signaling bias: Integrating simulations and biophysical experiments.

  2025cites this paper
• Quantum Chemical Exploration of Fentanyl and Its Analogs: Conformational Landscapes and Energetics in Solution

  2025cites this paper
• Biased signaling in drug discovery and precision medicine.

  2025cites this paper
• Historical perspectives and emerging trends in fentanyl use: Part 1 – Pharmacological profile

  2025cites this paper
• Opioid receptors in cardiovascular function

  2025cites this paper
• Biased Opioid Receptor Agonists: Balancing Analgesic Efficacy and Side-Effect Profiles

  2025cites this paper
• Non-invasive pharmacological profiling of novel endomorphin-2 analogs by confocal Raman spectroscopy and imaging.

  2025cites this paper
• Efficacy and Safety of SHR8554 on Postoperative Pain in Subjects with Moderate to Severe Acute Pain Following Orthopedic Surgery: A Multicenter, Randomized, Double-blind, Dose-explored, Active-controlled, Phase II/III Clinical Trial.

  2025cites this paper
• Estimation of ED50 and ED95 of Oliceridine Required to Suppress the Bronchoscopy Response in Patients Undergoing Fiberoptic Bronchoscopy Under Sedation with Cipepofol: An Up-and-Down Sequential Allocation Trial

  2025cites this paper
• Exploring Pharmacokinetic interactions between SHR8554, a µ-opioid receptor biased agonist, and Itraconazole in healthy Chinese subjects

  2025cites this paper
• Agonism and Biased Signaling.

  2025cites this paper
• Semi-synthesis in the exploration of opioid-targeting natural products

  2025cites this paper
• Role of β-Arrestin 2 in the antinociceptive and side effect profile of morphine and the novel mu opioid receptor agonists, kurkinorin and kurkinol

  2025cites this paper
• G Protein‐Coupled Receptor Signaling: Implications and Therapeutic Development Advances in Cancers

  2025cites this paper
• Tegileridine for moderate-to-severe acute pain following abdominal surgery: A randomized, double-blind, phase 3 clinical trial

  2025cites this paper
• Opioid Analgesics: Rise and Fall of Ligand Biased Signaling and Future Perspectives in the Quest for the Holy Grail

  2025cites this paper
• Effects of two structurally diverse positive allosteric modulators on signaling bias at the μ-opioid receptor.

  2025cites this paper
• OpenMMDL - Simplifying the Complex: Building, Simulating, and Analyzing Protein–Ligand Systems in OpenMM

  2025cites this paper
• Fine-Tuned Deep Transfer Learning Models for Large Screenings of Safer Drugs Targeting Class A GPCRs.

  2025cites this paper
• Opioid analgesics for sedation-based gastrointestinal endoscopy

  2025cites this paper
• Transformation of a Potent C9-Substituted Phenylmorphan into MOR Partial Agonists with Improvement of Metabolic Stability: An In Vitro, In Vivo, and In Silico Study.

  2025cites this paper
• Structural Determinants of Buprenorphine Partial Agonism at the μ‑Opioid Receptor

  2025cites this paper
• A Review on the Potential of Biased Agonism in the GPCR Signalosome for Therapeutic Efficacy

  2025cites this paper
• To Be Biased or Not to Be: A Play for G-Protein Coupled Receptors

  2025cites this paper
• Biased GPCR Signaling: Possible Mechanisms and Therapeutic Applications.

  2025cites this paper
• Impact of Intracellular Proteins on μ-Opioid Receptor Structure and Ligand Binding

  2024cites this paper
• Use Patterns of Classic, Novel, and Herbal Opioids

  2024cites this paper
• FLT3 signaling inhibition abrogates opioid tolerance and hyperalgesia while preserving analgesia

  2024cites this paper
• Discovery of cyanoguanidine derivatives as biased μ-opioid receptor agonists.

  2024cites this paper
• Signal profiles and spatial regulation of β-arrestin recruitment through Gβ5 and GRK3 at the μ-opioid receptor.

  2024cites this paper
• A prospective, historical-controlled evaluation of oliceridine for moderate or severe pain in patients with acute burn injuries (RELIEVE).

  2024cites this paper
• Peptide-derived ligands for the discovery of safer opioid analgesics.

  2024cites this paper
• Searching for Synthetic Opioid Rescue Agents: Identification of a Potent Opioid Agonist with Reduced Respiratory Depression.

  2024cites this paper
• Deletion of arrestin-3 does not reduce drug-seeking behavior in a longitudinal paradigm of oral morphine self-administration

  2024cites this paper
• Opioid system and related ligands: from the past to future perspectives

  2024cites this paper
• Pharmacokinetics and Safety of Oliceridine Fumarate Injection in Chinese Patients with Chronic Non-Cancer Pain: A Phase I, Single-Ascending-Dose, Open-Label Clinical Trial

  2024cites this paper
• Strategies for developing μ opioid receptor agonists with reduced adverse effects.

  2024cites this paper
• ERNEST COST action overview on the (patho)physiology of GPCRs and orphan GPCRs in the nervous system

  2024cites this paper
• Know your molecule: pharmacological characterization of drug candidates to enhance efficacy and reduce late-stage attrition

  2024cites this paper
• G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery

  2024cites this paper
• Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists.

  2024cites this paper
• Fentanyl and its derivatives: Pain-killers or man-killers?

  2024cites this paper
• Evolution and challenges of opioids in pain management: Understanding mechanisms and exploring strategies for safer analgesics

  2024cites this paper
• Ligand efficacy modulates conformational dynamics of the µ-opioid receptor

  2024cites this paper
• In Vitro Functional Profiling of Fentanyl and Nitazene Analogs at the μ-Opioid Receptor Reveals High Efficacy for Gi Protein Signaling.

  2024cites this paper
• Bivalent and bitopic ligands of the opioid receptors: The prospects of a dual approach

  2024cites this paper
• Activation of μ receptors by SR-17018 through a distinctive mechanism.

  2024cites this paper
• The synthetic peptide, PnPP-15, derived from the PnTx2-6 toxin of the spider Phoneutria nigriventer, induces peripheral antinociception involving neprilysin, opioid and cannabinoid systems

  2024cites this paper
• Bias translation: The final frontier?

  2024influential citation
• A dual nociceptin and mu opioid receptor agonist exhibited robust antinociceptive effect with decreased side effects.

  2023cites this paper
• Pharmacological and Physicochemical Properties Optimization for Dual-Target Dopamine D3 (D3R) and μ-Opioid (MOR) Receptor Ligands as Potentially Safer Analgesics.

  2023cites this paper
• Allosteric modulation of G protein-coupled receptors as a novel therapeutic strategy in neuropathic pain

  2023cites this paper
• Mu-opioid receptor selective superagonists produce prolonged respiratory depression

  2023cites this paper
• Three-Dimensional Structural Insights Have Revealed the Distinct Binding Interactions of Agonists, Partial Agonists, and Antagonists with the µ Opioid Receptor

  2023cites this paper
• Conformational dynamics of the μ-opioid receptor determine ligand intrinsic efficacy

  2023cites this paper
• Opioids and opioid receptors; understanding pharmacological mechanisms as a key to therapeutic advances and mitigation of the misuse crisis

  2023cites this paper
• Targeting Opioid Receptors in Addiction and Drug Withdrawal: Where Are We Going?

  2023cites this paper
• Oliceridine for the Management of Moderate to Severe Acute Postoperative Pain: A Narrative Review

  2023cites this paper
• Subacute toxicity evaluations of LPM3480392 in rats, a full µ-opioid receptor biased agonist

  2023cites this paper
• βγ G-proteins, but not regulators of G-protein signaling 4, modulate opioid-induced respiratory rate depression

  2023cites this paper
• Heroin and its metabolites: relevance to heroin use disorder

  2023cites this paper
• Functional selectivity of EM-2 analogs at the mu-opioid receptor

  2023cites this paper
• A non-hallucinogenic LSD analog with therapeutic potential for mood disorders.

  2023cites this paper
• One immune system plays many parts: The dynamic role of the immune system in chronic pain and opioid pharmacology.

  2023cites this paper
• Emerging Field of Biased Opioid Agonists.

  2023cites this paper
• CYX-5, a G-protein biassed MOP receptor agonist, DOP receptor antagonist and KOP receptor agonist, evokes constipation but not respiratory depression relative to morphine in rats

  2023cites this paper
• Chemical tools for the opioids.

  2023cites this paper
• Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB2 receptor

  2023cites this paper
• Current strategic trends in drug discovery: the present as prologue

  2023cites this paper
• Research progress on the role of orphan receptor GPR139 in neuropsychiatric behaviours.

  2023cites this paper
• μ opioid receptor carboxyl terminal-derived peptide alleviates morphine tolerance by inhibiting β-arrestin2

  2023cites this paper
• Alkoxy chain length governs the potency of 2-benzylbenzimidazole ‘nitazene’ opioids associated with human overdose

  2023cites this paper
• How do opioids control pain circuits in the brainstem during opioid-induced disorders and in chronic pain? Implications for the treatment of chronic pain.

  2023cites this paper
• Study of the mass balance, biotransformation and safety of [14C]SHR8554, a novel μ-opioid receptor injection, in healthy Chinese subjects

  2023cites this paper
• Direct Selection of DNA-Encoded Libraries for Biased Agonists of GPCRs on Live Cells

  2023cites this paper
• Evaluating the Pharmacokinetics of Fentanyl in the Brain Extracellular Fluid, Saliva, Urine, and Plasma of Newborns from Transplacental Exposure from Parturient Mothers Dosed with Epidural Fentanyl Utilizing PBPK Modeling

  2023cites this paper
• IUPHAR themed review: Opioid efficacy, bias, and selectivity

  2023cites this paper
• Respiratory Effects of Biased Ligand Oliceridine in Older Volunteers: A Pharmacokinetic–Pharmacodynamic Comparison with Morphine

  2022cites this paper
• The molecular associations in clathrin-coated pit regulate β-arrestin-mediated MAPK signaling downstream of μ-opioid receptor.

  2022cites this paper
• Therapeutic potential of allosteric modulators for the treatment of gastrointestinal motility disorders

  2022cites this paper
• Essential role of P-glycoprotein in the mechanism of action of oliceridine

  2022cites this paper
• Structure-based design of bitopic ligands for the µ-opioid receptor

  2022cites this paper
• Opioid MOP receptor agonists in late-stage development for the treatment of postoperative pain

  2022cites this paper
• Suboxone: History, controversy, and open questions

  2022cites this paper
• Signaling underlying kappa opioid receptor-mediated behaviors in rodents

  2022cites this paper
• Discovery of pyrazole‐1‐carboxamide derivatives as novel Gi‐biased μ‐opioid receptor agonists

  2022cites this paper
• Opioid epidemic: lessons learned and updated recommendations for misuse involving prescription versus non-prescription opioids

  2022cites this paper
• [Biased Signaling through G Protein-coupled Receptors].

  2022cites this paper
• Molecular recognition of morphine and fentanyl by the human μ-opioid receptor.

  2022cites this paper
• Opioids and Vitamin C: Known Interactions and Potential for Redox-Signaling Crosstalk

  2022cites this paper
• Mechanism of opioid addiction and its intervention therapy: Focusing on the reward circuitry and mu‐opioid receptor

  2022cites this paper